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• Newly diagnosed HGG
• T1+C and DSC scans at MR Sim and 3-
week F/U
• At least 6-month F/U
Statistical Analysis
• Unpaired t-test to determine if early
rCBV change and Fisher’s exact test 
to determine if MGMT methylation 
status are significantly different
between PsP and DP groups
Patient Categorization
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Rationale
• Patients with high grade glioma (HGG) often 
demonstrate increased contrast enhancement 
following chemoradiation (CRT) that may 
represent pseudoprogression (PsP) or disease 
progression (DP)
• PsP occurs within 6 months following CRT, 
results from treatment-induced changes, and 
is associated with improved survival 
• Diagnosis of PsP vs DP impacts clinical 
decision making
• Post-RT relative cerebral blood volume (rCBV) 
used as marker to differentiate PsP vs DP
Primary Objective
• Retrospectively determine if a change in 
rCBV within the first 3 weeks of CRT can 
predict PsP vs DP for patients with HGG
Secondary Objectives
• Determine if MGMT Methylation status 
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MR Sim rCBV​ 0.82 -1.12 – 0.90​
Mean​ 0.85​ 0.81 0.92​
Median​ 0.51 0.37 0.67​
3-week rCBV​ 0.44​ -1.51 - 0.70​
Mean​ 0.92​ 0.74​ 1.15​
Median​ 0.63 0.51 0.85​
Change 
in rCBV​
0.15​ -0.71 – 0.12​
Mean​ 0.06​ -0.06​ 0.23​
Median​ 0.11​ 0.06 0.18​
*Unpaired t-test
• Preclinical literature in GBM mouse models 
suggests that radiation-induced microvascular 
changes take time
• Angiogenesis inhibition and a significant 
decrease in perfusion seen at 2 weeks 
post-treatment (Seo et al. 2019, Kioi et al. 
2010)
• Vascular changes may be delayed in human 
tumors comparative to animal models 
(Eberhard et al. 2000)
All 
(n=26)
PsP (n=13) DP (n=11)
Age, median (range), 
year
61 (28-74) 62 (28-74) 57 (48-67)
Gender, male (%) 15 (58) 9 (69) 6 (55)
MGMT Methylation 
Status
Methylated (%) 8 (31) 5 (38) 3 (27)
Unmethylated (%) 14 (54) 5 (38) 7 (64)
Unknown (%) 4 (15) 3 (23) 1 (9)
Race, white (%) 24 (92) 13 (100) 9 (82)
KPS (%)
≥ 70 24 (92) 13 (100) 8 (73)
< 70 2 (8) 0 (0) 2 (18)
Histology (%)
GBM 22 (85) 9 (69) 11 (100)
Astrocytoma 3 (13) 3 (23) 0 (0)
Oligodendroglioma 1 (4) 1 (8) 0 (0)
Tumor Segmentation & Post-
processing
• Manual contouring on Axial MRIs using 
RayStation Non-Clinical – 10B DTK
• Leakage correction algorithm run on 
MATLAB 10a
• rCBV:
3 𝑤𝑒𝑒𝑘 𝑓/𝑢 𝑇𝑢𝑚𝑜𝑟 𝑟𝐶𝐵𝑉
3 𝑤𝑒𝑒𝑘 𝑓/𝑢 𝑁𝐴𝑊𝑀 𝑟𝐶𝐵𝑉
−
𝑀𝑅 𝑆𝑖𝑚 𝑇𝑢𝑚𝑜𝑟 𝑟𝐶𝐵𝑉
𝑀𝑅 𝑆𝑖𝑚 𝑁𝐴𝑊𝑀 𝑟𝐶𝐵𝑉
= 𝐶ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑟𝐶𝐵𝑉 𝐷𝑢𝑟𝑖𝑛𝑔 𝑅𝑇
Future Directions
• Determine if a change in rCBV between MR 
Sim and 1-month post-CRT predicts PsP vs 
DP
• Even if rCBV as an independent biomarker is 
not predictive, investigate whether it serves as 
useful input for a mechanistic mathematical 










MR Sim rCBV​ 0.90 -1.10 – 1.23​
Mean​ 0.95 0.98 0.92​
Median​ 0.67 0.72 0.67​
3-week rCBV​ 0.85​ -1.24 – 1.05​
Mean​ ​1.10 1.05​ 1.15​
Median​ 0.84 0.75 0.85​
Change 
in rCBV​
0.28​ -0.49 – 0.16
Mean​ 0.15 0.07 0.23​
Median​ 0.12 0.12 0.18​
Discussion
